- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Senate passes Drug Quality and Security Act
- Facing pharmacy trends for the remainder of the year
LAKE FOREST, Ill. — Hospira posted sales of $1 billion during second quarter 2013, a 0.7% decrease compared with second quarter 2012, the generic drug maker said.
Hospira, which specializes in making generic injectables, also posted $318.7 million gross profit, a 12.4% increase over second quarter 2012's $283.5 million.
"Results for the second quarter were in line with our expectations," CEO F. Michael Ball said. "In addition, it was a quarter of several milestone achievements for Hospira, such as the positive opine from the European Medicines Agency on our biosimilar infliximab, Inflectra, and the U.S. launch of the new premix versions of our branded sedation agent, Precedex."
Infliximab is a biosimilar version of Johnson & Johnson's Remicade, used to treat autoimmune disorders like arthritis, psoriasis and inflammatory bowel disease.